Immuno Cure Holding (HK) Limited
- Biotech or pharma, therapeutic R&D
- Medical device or technology
Immuno Cure Holding (HK) Limited (“Immuno Cure”) is a biotechnology group focusing on innovative immunotherapies for cancers, inflammatory and infectious diseases. Our patented technology platforms include the “PD-1 Enhanced DNA Vaccine Platform” and the “Electroporation Vaccine Delivery Platform”. Our core product ICVAX, a HIV therapeutic DNA vaccine, together with EP vaccine delivery, has recently completed Phase I clinical trial with promising safety and immunogenicity results. These encouraging data represent a significant step towards achieving antiretroviral therapy (ART)-free virological control in people living with HIV (PLWH) by ICVAX and ultimately accomplishing as a functional cure of HIV/AIDS.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}